# Oskar Slotboom

> Oskar Slotboom is a Series A investor at BioGeneration Ventures backing Therapeutics. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [BioGeneration Ventures](https://shizune.co/investors/profile/biogeneration-ventures)
- Location: Naarden, The Netherlands
- Total investments: 6
- Last investment: Nov 2022
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/oskar-slotboom-60b6051/

Oskar Slotboom is a Series A investor at BioGeneration Ventures in Naarden focused on Therapeutics and Biotechnology. Oskar Slotboom is based out of Naarden, North Holland and is the Managing Partner of BioGeneration Ventures. Oskar previously worked at Avantium as a Chief Commercial Officer. Oskar Slotboom attended the INSEAD .

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 3 | 50% |
| Biotechnology | 2 | 33% |
| Manufacturing | 2 | 33% |
| Pharmaceutical | 2 | 33% |
| Medical | 1 | 17% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 33% |
| Series C | 2 | 33% |
| Seed | 1 | 17% |
| Series B | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| The Netherlands | 3 | 50% |
| Germany | 1 | 17% |
| United Kingdom | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CatalYm | Catalym develops antibodies against a placental factor which is overexpressed by various tumour types. | $51.6M | Series C | Nov 22, 2022 |  |
| NorthSea Therapeutics | NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generatedpipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models. | $80M | Series C | Dec 17, 2021 |  |
| Dunad Therapeutics | Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies. | $24M | Series A | Nov 02, 2021 |  |
| VarmX | VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer. | $8.2M | Series A | Jul 02, 2018 |  |
| Mellon Medical | Mellon Medical provides suturing tools for surgeons to improve medical procedures. The company's goal is to help medical specialists improve patient outcomes by providing them with the best possible suturing tools. It commercializes surgical instruments to allow single-handed stitching, enabling efficient and effective suturing of tubular andlayered structures.Mellon Medical was established in 2013 and is headquartered in Nijmegen, Gelderland. | $6.4M | Series B | Aug 30, 2017 |  |
| VarmX | VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer. | $1.1M | Seed | Jun 27, 2017 |  |

6 of 6 investments shown.

## Co-investors
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 4 deals together
- [InnovationQuarter](https://shizune.co/investors/profile/innovation-quarter) — VC Fund, 2 deals together
- [New Science Ventures](https://shizune.co/investors/profile/new-science-ventures) — VC Fund, 2 deals together
- [Bayern Kapital](https://shizune.co/investors/profile/bayern-kapital) — VC Fund, 1 deal together
- [BOM](https://shizune.co/investors/profile/brabantse-ontwikkelings-maatschappij-bom) — VC Fund, 1 deal together
- [Brandon Capital](https://shizune.co/investors/profile/brandon-capital-partners) — VC Fund, 1 deal together

## About BioGeneration Ventures

VC Fund · Naarden, The Netherlands

BioGeneration Ventures is investing in the next generation of Life Sciences companies in the Netherlands. BioGeneration Ventures invests in Dutch start-up and early stage life sciences companies. The BioGeneration Ventures team is specialized in the evaluation and management of early stage companies. Their involvement goes beyond thefinancial investment. They work closely with scientists, academic institutions, entrepreneurs and industry experts to accelerate the development and to optimize the commercial potential of their portfolio company's technologies. BioGeneration Ventures began operating in 2006 and the fund is backed by the Netherlands Genomics Initiative (NGI) and the Netherlands Organisation for Scientific Research (NWO) in combination with the holding company of Leiden University and ABN-AMRO Capital as lead private investors.

5 contacts available at BioGeneration Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Daniela Couto | General Partner | https://shizune.co/investors/profile/daniela-couto |
| Edward van Wezel | Founder and Managing Partner | https://shizune.co/investors/profile/edward-van-wezel |
| Joost Holthuis | Venture Partner | https://shizune.co/investors/profile/joost-holthuis |
| Oskar Slotboom | Managing Partner | https://shizune.co/investors/profile/oskar-slotboom |
| Elena Ritsou | Venture Partner | https://shizune.co/investors/profile/elena-ritsou |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Oskar Slotboom invest in?

Oskar Slotboom invests primarily in Therapeutics, Biotechnology and Manufacturing startups, most often at Series A and Series C stage. Most of the 6 investments tracked by Shizune back companies in The Netherlands. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Oskar Slotboom last invest?

The most recent investment recorded for Oskar Slotboom closed in Nov 2022. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co